Pilot Projects Program

试点项目计划

• 批准号: 10685599
• 负责人: GARY O RANKIN
• 金额: $ 6.79万
• 依托单位: WEST VIRGINIA UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-08-15 至 2027-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10685599
• 关键词: Acceleration; Address; Alzheimer' s Disease; Applications Grants; Area; Cardiovascular Diseases; Chronic lung disease; Clinical Investigator; Clinical Research; Clinical Sciences; Collaborations; Complement; Conceptions; Data; Development; Educational workshop; Emerging Communicable Diseases; Ensure; Extramural Activities; Foundations; Funding; Funding Mechanisms; Funding Opportunities; Future; Goals; Grant; Health; Health Priorities; Incentives; Infrastructure; Institution; Investigator-Initiated Research; Malignant Neoplasms; Manuscripts; Medical; Medical Students; Mentors; Mission; Outcome; Pathway interactions; Pilot Projects; Positioning Attribute; Process; Qualifying; Research; Research Personnel; Rural Health; Science; Secure; Site; Stroke; Technology; Time; Training; Translational Research; Trust; Universities; West Virginia; Work; addiction; bench to bedside; career development; clinical application; commercialization; community engagement; experience; falls; flexibility; implementation facilitation; improved; innovation; innovative technologies; novel; practice-based research network; programs; response; success; translational scientist

The Pilot Project Program (PPP) is crucial to the development and support of clinical and translational research for the West Virginia Clinical and Translational Science Institute (WVCTSI). The PPP provides the infrastructure to set early-stage investigators (ESIs) on the path that will provide meaningful research to positively impact West Virginians, in rapidly advancing and changing health-related fields. While qualified researchers exist within the state, the PPP provides a platform to match expertise within and across WVCTSI partner institutions. To accomplish its goals, the PPP will (1) provide innovative funding mechanisms to facilitate clinical and translational research, (2) work to improve the quality and impact of clinical and translational research in the state, and (3) stimulate ESI development. Toward these goals, the PPP will provide several funding mechanisms to enhance clinical and translational research with the Open Grant serving as a primary mechanism for supporting investigator-initiated research. Two new PPP funding opportunities will establish team science-based initiatives (Bench-to-Bedside Grants) and create a new career development initiative through the Fellows Grant program. The new Rapid Response Grant will allow for flexibility in targeting emerging health issues within the state and getting funding to meritorious projects in a shortened time frame. Promoting the development and commercialization of new medically-related technology is the focus of the novel Launch Grant program, with the Jumpstart Grant providing funding to complete a manuscript or obtain key preliminary data for an extramural grant application. Applications for PPP funding mechanisms will receive priority if they are focused on WVCTSI health priority areas, are led by an ESI and/or a clinician, are from a partner site, or use the Practice-Based Research Network. Incentives will be provided for applications that provide a medical student research experience. We will also provide an A1 mechanism whereby investigators with promising projects that fall short of the funding line will be provided mentoring and the opportunity to resubmit an improved proposal. In addition, improving the success rate of pilot projects submitted by partner institution investigators is a priority. Indeed, the trust and camaraderie developed among WVCTSI partner institutions will facilitate implementation of impactful WV science through the PPP. The PPP will work synergistically with other WVCTSI Cores to mentor and train network investigators in clinical and translational research to improve the quality and impact of clinical and translational research in West Virginia and increase the success of WVCTSI investigators in securing extramural funding.

试点项目计划（PPP）对于临床和转化研究的发展和支持至关重要 西弗吉尼亚临床和转化科学研究所（WVCTSI）。PPP提供基础设施 让早期研究人员（ESI）走上提供有意义研究的道路，对西方产生积极影响。 在快速发展和变化的健康相关领域，虽然合格的研究人员存在于 PPP提供了一个平台，以匹配WVCTSI合作机构内部和之间的专业知识。到 为了实现其目标，PPP将（1）提供创新的资助机制，以促进临床和转化 研究，（2）努力提高该州临床和转化研究的质量和影响，以及（3） 促进ESI发展。为了实现这些目标，PPP将提供几种供资机制， 临床和转化研究与开放赠款作为支持的主要机制， 研究发起人。两个新的公私伙伴关系资助机会将建立基于科学的团队倡议 （从工作台到床边赠款），并通过研究员助学金计划创建一个新的职业发展计划。 新的快速反应赠款将允许灵活地针对该州内新出现的健康问题， 在更短的时间内为有价值的项目获得资金。促进开发和 新的医疗相关技术的商业化是新的发射资助计划的重点， 快速启动赠款提供资金，以完成手稿或获得关键的初步数据，为校外 补助金申请如果公私伙伴关系供资机制的申请侧重于WVCTSI，则将获得优先考虑 健康优先领域，由ESI和/或临床医生领导，来自合作伙伴站点，或使用基于实践的 中国互联网.将为提供医学生研究的申请提供奖励 体验.我们还将提供一个A1机制，使研究人员与有前途的项目，但没有达到 将为资金项目的所有成员提供辅导，并有机会重新提交改进后的提案。此外，本发明还提供了一种方法， 提高伙伴机构调查人员提交的试点项目的成功率是一个优先事项。持续增 WVCTSI伙伴机构之间建立的信任和友情将有助于实施有效的 通过PPP的WV科学。PPP将与其他WVCTSI核心协同工作，指导和培训 临床和转化研究的网络研究者，以提高临床和转化研究的质量和影响， 在西弗吉尼亚州的转化研究，并增加WVCTSI调查人员在确保校外的成功 经费